Evommune
Evommune's revenue rose 85.7% to $13 million in fiscal 2025. Its operating margin was −623.6%, up from −1,000.2% a year earlier. Free cash flow was −$77 million. The diluted share count rose 306.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What Evommune does
Evommune is a clinical-stage biotechnology company, meaning it is testing drug candidates in people and has none approved for sale. It is developing therapies for chronic inflammatory diseases, starting with chronic spontaneous urticaria (CSU, a long-lasting itchy skin rash), atopic dermatitis (AD, a skin condition) and ulcerative colitis (UC, a bowel disease).
It has two product candidates in Phase 2 trials. EVO756, an oral small molecule that blocks a receptor called MRGPRX2, is being developed for CSU and AD. EVO301 is being developed for AD and UC. The company is currently running a Phase 2b trial of EVO756 in CSU, and says it intends to move more preclinical programs into clinical development.
Evommune has existed since 2020 and says it has invested most of its resources in developing its product candidates, building its patents, planning and staffing. It had 48 full-time employees at December 31, 2025.
Its biggest risks, as it describes them
- It has no approved products and a limited operating history, and it may not reach profitability.
- Needing more money, which could dilute shareholders or force it to give up rights to its candidates.
- Clinical trials that fail or show weaker results than hoped, or regulators that do not approve its candidates.
- It has no marketing, sales or distribution capabilities and may need to spend heavily to build them.
- Licensed intellectual property rights that could end early if it fails to meet its license obligations.
Income statement
Evommune lost money in fiscal 2025: a net loss of $69 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | 72 | 149 |
| Debt incl. finance leases | — | — |
| Net debt (negative means net cash) | — | — |
| Net debt to EBITDA | — | — |
| Debt to equity | — | — |
| Interest coverage | −2,059.2x | −11,581.6x |
| Current ratio | 2.6x | 8.6x |
| Quick ratio | 2.6x | 8.6x |
Cash flow
Projections
Project Evommune's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $163,610 of Evommune shares on the open market, and 6 insiders sold $2.3 million, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Kyle CarverChief Financial Officer | Bought | 1,000 | $13.26 | $13,260 | Form 4 |
| Jul 7, 2026 | Arthur S KirschDirector | Bought | 10,000 | $13.30 | $133,000 | Form 4 |
| Jun 22, 2026 | Janice Suzann DrewChief of Dev. Operations | Sold plan | 20,000 | $22.63 | $452,600 | Form 4 |
| Jun 22, 2026 | Luis C. PenaPresident & CEO, Director | Sold plan | 7,438 | $22.71 | $168,917 | Form 4 |
| Jun 22, 2026 | Jeegar Pravinkumar PatelChief Scientific Officer | Sold plan | 1,488 | $22.50 | $33,480 | Form 4 |
| Jun 2, 2026 | David E CohenDirector | Sold plan | 6,056 | $20.33 | $123,094 | Form 4 |
| Jun 1, 2026 | Luis C. PenaPresident & CEO, Director | Sold plan | 16,787 | $22.74 | $381,736 | Form 4 |
| Jun 1, 2026 | Jeegar Pravinkumar PatelChief Scientific Officer | Sold plan | 16,687 | $22.74 | $379,462 | Form 4 |
| May 28, 2026 | Kyle CarverChief Financial Officer | Sold plan | 18,175 | $22.84 | $415,117 | Form 4 |
| May 28, 2026 | Gregory S. MossChief Business & Legal Officer | Sold plan | 14,223 | $22.83 | $324,711 | Form 4 |
| Dec 19, 2025 | Robert Lorne HopfnerDirector, 10% owner | Bought | 1,000 | $17.35 | $17,350 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY25 |
|---|---|
| Piotroski F-score | — |
| Rule of 40 | −504.1% |
| Altman Z'' | 9.47 |
| Accruals ratio | 5.0% |
The nine F-score tests
| Test | FY25 |
|---|---|
| Net income is positive | Fail |
| Cash from operations is positive | Fail |
| Return on assets rose | — |
| Cash from operations exceeds net income | Fail |
| Debt fell relative to assets | — |
| Current ratio rose | Pass |
| Share count didn't rise | Fail |
| Gross margin rose | — |
| Revenue rose relative to assets | — |
| F-score | — |
Compare
Put Evommune side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Evommune | FY25 | 85.7% | −623.6% | −589.8% | — | — | — | |
| Tonix Pharmaceuticals | FY25 | 29.9% | −959.0% | −787.5% | — | — | — | Compare |
| Pyxis Oncology | FY25 | −14.2% | −609.2% | −458.3% | — | — | — | Compare |
| Prelude Therapeutics | FY25 | 73.4% | −861.3% | −464.3% | — | — | — | Compare |
| Opus Genetics | FY25 | 29.1% | −271.9% | — | — | — | 3 | Compare |
2 years of figures
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | 7 | 13 |
| Revenue growth | — | 85.7% |
| Gross profit | — | — |
| Research and development | 64 | 74 |
| Operating income | −70 | −81 |
| Net income | −67 | −69 |
| Diluted EPS (US$) | −45.29 | −11.22 |
| Diluted shares (millions) | 2 | 6 |
| Cash flow | ||
| Cash from operations | −58 | −76 |
| Capital expenditure | 0 | 0 |
| Free cash flow | −58 | −77 |
| Dividends paid | 0 | 0 |
| Share buybacks | 0 | 0 |
| Acquisitions | 0 | 0 |
| Stock-based compensation | 2 | 6 |
| Balance sheet at fiscal year end | ||
| Cash and short-term investments | 72 | 149 |
| Debt incl. finance leases | — | — |
| Total assets | 76 | 225 |
| Total liabilities | 28 | 19 |
| Shareholders' equity | −144 | 206 |
| Margins and ratios | ||
| Gross margin | — | — |
| Operating margin | −1,000.2% | −623.6% |
| Net margin | −954.4% | −529.8% |
| Free cash flow margin | −832.6% | −589.8% |
| Rule of 40 (growth + FCF margin) | — | −504.1% |
| Return on capital | — | — |
| Return on equity | — | −224.6% |
| Return on assets | — | −45.8% |
| Net debt to EBITDA | — | — |